MIRAGEN THERAPEUTICS, INC. Contracts & Agreements

Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 27, 2024)

Form of Indemnity Agreement between the Registrant and each of its directors and executive officers (Filed With SEC on February 27, 2024)

Lara Meisner Employment Agreement, dated May 11, 2023 (Filed With SEC on February 27, 2024)

Thomas Ciulla Employment Agreement, dated January 12, 2023 (Filed With SEC on February 27, 2024)

Seth Harmon Employment Agreement, dated April 24, 2023 (Filed With SEC on February 27, 2024)

Amendment to Seth Harmon Employment Agreement, dated September 28, 2023 (Filed With SEC on February 27, 2024)

Jennifer Tousignant Employment Agreement, dated January 10, 2024 (Filed With SEC on February 27, 2024)

Form of Stock Option Grant Notice and Stock Option Agreement under 2016 Equity Incentive Plan (Filed With SEC on February 27, 2024)

Form of Restricted Stock Award Agreement under the 2016 Equity Incentive Plan (Filed With SEC on February 27, 2024)

2016 Amended and Restated Employee Stock Purchase Plan (Filed With SEC on February 27, 2024)

Underwriting Agreement, by and among the Company and the Representatives, dated as of January 17, 2024 (Filed With SEC on January 19, 2024)

First Amendment to Loan and Security Agreement, dated as of August 7, 2023, among the Viridian Therapeutics, Inc., certain of its subsidiaries from time to time party thereto, the... (Filed With SEC on November 13, 2023)

Stephen Mahoney Employment Agreement, dated October 27, 2023 (Filed With SEC on November 13, 2023)

Thomas Beetham Employment Agreement, dated October 27, 2023 (Filed With SEC on November 13, 2023)

Securities Purchase Agreement, dated October 30, 2023, by and between the Company and the Purchasers signatory thereto (Filed With SEC on October 30, 2023)

Registration Rights Agreement, dated October 30, 2023, by and between the Company and the Purchasers signatory thereto (Filed With SEC on October 30, 2023)

Viridian Therapeutics, Inc. Amended and Restated 2016 Equity Incentive Plan (Filed With SEC on June 16, 2023)

Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 9, 2023)

Scott Myers Employment Agreement, dated December 29, 2022 (Filed With SEC on February 6, 2023)

Jonathan Violin General Release and Separation and Consulting Agreement, dated February 6, 2023 (Filed With SEC on February 6, 2023)

Third Amendment to Lease by and between R (Filed With SEC on November 14, 2022)

Underwriting Agreement by and among the Company and the Representatives, dated as of August 16, 2022 (Filed With SEC on August 19, 2022)

Second Amendment to Lease by and between the Registrant and Watch City Ventures MT, LLC dated as of April 13, 2022 (Filed With SEC on August 15, 2022)

Viridian Therapeutics, Inc. Amended & Restated 2016 Equity Incentive (Filed With SEC on August 15, 2022)

Carrie Melvin Employment Agreement, dated May 25, 2022 (Filed With SEC on June 23, 2022)

Loan and Security Agreement, dated as of April 1, 2022, among Viridian Therapeutics, Inc., certain of its subsidiaries from time to time party thereto, the Lenders from time to... (Filed With SEC on April 5, 2022)

Subscription Agreement, by and between the Registrant and Xencor, dated as of December 2, 2021 (Filed With SEC on March 11, 2022)

Waltham Lease between Registrant and Watch City Ventures MT, LLC dated as of January 13, 2020 (Filed With SEC on November 5, 2021)

First amendment to Waltham Lease between Registrant and Watch City Ventures MT, LLC dated July 6, 2021 (Filed With SEC on November 5, 2021)

Underwriting Agreement by and among the Company and the Representatives, dated as of September 20, 2021 (Filed With SEC on September 23, 2021)

Open Market Sale Agreement (Filed With SEC on August 12, 2021)

Fifth Addendum to Lease by and between Registrant and Crestview, LLC, dated as of March 26, 2021 (Filed With SEC on August 12, 2021)

Kristian Humer Employment Agreement, dated June 9, 2021 (Filed With SEC on July 26, 2021)

Consulting Agreement, dated as of February 1, 2021, by and between the Registrant and William S. Marshall, Ph.D (Filed With SEC on May 7, 2021)

Fifth Addendum to Lease by and between Registrant and Crestview, LLC, dated as of March 26, 2021 (Filed With SEC on May 7, 2021)

Open Market Sale Agreement, dated April 23, 2021, by and between Viridian Therapeutics, Inc. and Jefferies LLC (Filed With SEC on April 26, 2021)

Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 26, 2021)

Technology License Agreement, by and between the Registrant and Xencor, Inc., dated as of December 16, 2020 (Filed With SEC on March 26, 2021)

Subscription Agreement, by and between the Registrant and Xencor, Inc., dated as of December 16, 2020 (Filed With SEC on March 26, 2021)

Employment Agreement by and between the Registrant and Barrett Katz, M.D., dated as of January 18, 2021 (Filed With SEC on March 26, 2021)

Separation and Release Agreement, dated as of September 27, 2020 by and between the Registrant and Diana Escolar, M.D (Filed With SEC on March 26, 2021)

Amended and Restated 2016 Equity Incentive Plan (Filed With SEC on March 26, 2021)

Form of 2020 Incentive Stock Option Grant Notice under Viridian Therapeutics, Inc. 2020 Stock Incentive Plan (Filed With SEC on March 26, 2021)

Employment Agreement by and between the Company and Jonathan Violin, dated as of January 15, 2021 (Filed With SEC on January 20, 2021)

Separation and Release Agreement by and between the Company and Lee Rauch, dated as of January 15, 2020 (Filed With SEC on January 20, 2021)

License Agreement, by and between the Company and ImmunoGen, dated as of October 12, 2020 (Filed With SEC on December 9, 2020)

Amendment to Research Subaward Agreement, entered into as of August 11, 2020, by and between Registrant and Yale University (Filed With SEC on November 12, 2020)

Separation Agreement, dated as of October 15, 2020, by and between the Registrant and William S. Marshall, Ph.D (Filed With SEC on November 12, 2020)

Consulting Agreement, dated as of October 16, 2020, by and between the Registrant and William S. Marshall, Ph.D (Filed With SEC on November 12, 2020)

Bonus Agreement, dated as of September 14, 2020, by and between the Registrant and Jason Leverone (Filed With SEC on November 12, 2020)

Registration Rights Agreement, dated as of October 30, 2020, by and among the Registrant and certain purchasers (Filed With SEC on November 12, 2020)

Agreement and Plan of Merger, dated October 27, 2020, by and among Miragen Therapeutics, Inc., Oculus Merger Sub I, Inc., Oculus Merger Sub II, LLC and Viridian Therapeutics, Inc (Filed With SEC on October 28, 2020)

Securities Purchase Agreement, dated as of October 27, 2020, by and among Miragen Therapeutics, Inc. and each purchaser identified on Annex A thereto (Filed With SEC on October 28, 2020)

Form of Registration Rights Agreement, by and among Miragen Therapeutics, Inc. and certain purchasers (Filed With SEC on October 28, 2020)

Bonus Agreement, dated as of September 27, 2020, by and between the Company and Diana Escolar, M.D (Filed With SEC on October 1, 2020)

Form of Separation Agreement, dated as of September 14, 2020, by and between the Company and William S. Marshall, Ph.D (Filed With SEC on September 17, 2020)

Form of Consulting Agreement, dated as of September 14, 2020, by and between the Company and William S. Marshall, Ph.D (Filed With SEC on September 17, 2020)

Amended and Restated Employment Agreement, dated as of September 14, 2020, by and between the Company and Lee Rauch (Filed With SEC on September 17, 2020)

Form of Bonus Agreement, dated as of September 14, 2020, by and between the Company and Jason Leverone (Filed With SEC on September 17, 2020)

Form of Bonus Agreement, dated as of September 14, 2020, by and between the Company and Diana Escolar, M.D (Filed With SEC on September 17, 2020)

Employment Agreement by and between the Registrant and Lee Rauch, dated as of June 16, 2020 (Filed With SEC on June 19, 2020)

Fourth Addendum to Lease by and between Registrant and Crestview, LLC, dated as of April 7, 2020 (Filed With SEC on May 8, 2020)

Amendment to Research Subaward Agreement, entered into as of April 7, 2020, by and between Registrant and Yale University (Filed With SEC on May 8, 2020)

Deferral Agreement between Silicon Valley Bank and the Registrant effective as of April 6, 2020 (Filed With SEC on May 8, 2020)

U.S. Small Business Administration Paycheck Protection Program Note, by and between Miragen Therapeutics, Inc. and Silicon Valley Bank, dated April 21, 2020 (Filed With SEC on April 27, 2020)

Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on March 13, 2020)

Employment Agreement by and between the Registrant and Diana Escolar, M.D., dated as of February 20, 2020 (Filed With SEC on March 13, 2020)

Third Addendum to Lease by and between Registrant and Crestview, LLC, dated as of January 17, 2020 (Filed With SEC on March 13, 2020)

Underwriting Agreement, dated February 7, 2020, by and among Miragen Therapeutics, Inc. and Oppenheimer & Co. Inc (Filed With SEC on February 7, 2020)

Form of Warrant to Purchase Common Stock (Filed With SEC on February 7, 2020)

Registration Rights Agreement, dated December 11, 2019, between Miragen Therapeutics, Inc. and Aspire Capital Fund, LLC (Filed With SEC on December 11, 2019)

Common Stock Purchase Agreement, dated December 11, 2019 between Miragen Therapeutics, Inc. and Aspire Capital Fund, LLC (Filed With SEC on December 11, 2019)

Amendment No. 1 to Amended and Restated License Agreement, effective as of August 8, 2019, by and between Registrant and Roche Innovation Center Copenhagen A/S (Filed With SEC on November 8, 2019)

Amendment to Research Subaward Agreement, entered into as of October 11, 2019 and effective as of August 12, 2019, by and between Registrant and Yale University, as amended (Filed With SEC on November 8, 2019)

Assignment and Assumption Agreement, dated as of October 28, 2019, by and between the Registrant, The Leukemia & Lymphoma Society, Inc. and LLS TAP Miragen, LLC (Filed With SEC on October 31, 2019)

Amendment to Research Subaward Agreement, entered into as of March 7, 2019 and effective as of September 1, 2018, by and between Registrant and Yale University, as amended (Filed With SEC on May 9, 2019)

Eighth Amendment of the License and Collaboration Agreement, entered into as of January 21, 2019 and effective as of January 7, 2019, by and between Registrant and Les... (Filed With SEC on March 14, 2019)

Common Stock Purchase Agreement, dated August 6, 2018, by and between the Registrant and The Leukemia & Lymphoma Society, Inc (Filed With SEC on November 7, 2018)

Seventh Amendment of the License and Collaboration Agreement, entered into as of April 3, 2018 and effective as of March 26, 2018, by and between Registrant and Les Laboratoires... (Filed With SEC on May 9, 2018)

Warrant to Purchase Stock between Miragen Therapeutics, Inc. and Silicon Valley Bank, dated April 30, 2015 (Filed With SEC on March 15, 2018)

Underwriting Agreement, dated February 8, 2018, by and among Miragen Therapeutics, Inc. and Jefferies LLC, Evercore Group L.L.C. and Deutsche Bank Securities Inc (Filed With SEC on February 9, 2018)

Amended and Restated Loan and Security Agreement between Miragen Therapeutics, Inc. and Silicon Valley Bank, dated November 14, 2017 (Filed With SEC on November 15, 2017)

Warrant to Purchase Stock between Miragen Therapeutics, Inc. and Silicon Valley Bank, dated November 14, 2017 (Filed With SEC on November 15, 2017)

Sixth Amendment of the License and Collaboration Agreement, effective as September 27, 2017, by and between Registrant and Les Laboratoires Servier, on the first part, and... (Filed With SEC on November 9, 2017)

FIFTH AMENDMENT OF THE LICENSE AND COLLABORATION AGREEMENT (Filed With SEC on August 11, 2017)

MIRAGEN THERAPEUTICS, INC. RESTRICTED STOCK AWARD GRANT NOTICE (2016 EQUITY INCENTIVE PLAN) (Filed With SEC on May 11, 2017)

Miragen Therapeutics, Inc. Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on May 11, 2017)

Research Subaward Agreement Amendment (Filed With SEC on May 11, 2017)

MIRAGEN THERAPEUTICS, INC. COMMON STOCK SALES AGREEMENT (Filed With SEC on March 31, 2017)

SUBSCRIPTION AGREEMENT (Filed With SEC on December 2, 2016)

SIGNAL GENETICS, INC. RESTRICTED STOCK UNIT GRANT AGREEMENT UNDER THE 2014 STOCK INCENTIVE PLAN (Filed With SEC on December 2, 2016)

SIGNALGENETICS, INC. STOCK OPTION GRANT AGREEMENT UNDER THE 2014 STOCK INCENTIVE PLAN (Filed With SEC on December 2, 2016)

SIGNALGENETICS, INC. RESTRICTED STOCK UNIT GRANT AGREEMENT UNDER THE 2014 STOCK INCENTIVE PLAN (Filed With SEC on December 2, 2016)

INDEMNITY AGREEMENT (Filed With SEC on December 2, 2016)

MIRAGEN THERAPEUTICS, INC. EMPLOYMENT AGREEMENT (Filed With SEC on December 2, 2016)

SIGNAL GENETICS, INC. 2016 EQUITY INCENTIVE PLAN STOCK OPTION GRANT NOTICE (Filed With SEC on December 2, 2016)

LEASE CRESTVIEW, LLC (as Landlord) and MIRAGENTHERAPEUTICS, INC. (as Tenant) 1 LEASE (Filed With SEC on December 2, 2016)

FIRST ADDENDUM (Filed With SEC on December 2, 2016)

SECOND ADDENDUM (Filed With SEC on December 2, 2016)

EXCLUSIVE PATENT LICENSE AGREEMENT BETWEEN THE UNIVERSITYOF TEXAS SYSTEM AND MIRAGEN THERAPEUTICS, INC. TABLE OF CONTENTS (Filed With SEC on December 2, 2016)

EXCLUSIVE PATENT LICENSE AGREEMENT BETWEEN THE UNIVERSITY OF TEXAS SYSTEM AND MIRAGEN THERAPEUTICS, INC. TABLE OF CONTENTS (Filed With SEC on December 2, 2016)

LICENSE AND COLLABORATION AGREEMENT (Filed With SEC on December 2, 2016)

AMENDMENT No. 1 TO LICENSE AND COLLABORATION AGREEMENT (Filed With SEC on December 2, 2016)

AMENDED AND RESTATED LICENSE AGREEMENT (Filed With SEC on December 2, 2016)

License and Collaboration Agreement by and between MiragenTherapeutics, Inc. and Les Laboratoires Servier and Institut deRecherches Servier LICENSE AND COLLABORATION AGREEMENT (Filed With SEC on December 2, 2016)

FIRST AMENDMENT OF THELICENSE AND COLLABORATION AGREEMENT (Filed With SEC on December 2, 2016)

SECOND AMENDMENT OF THELICENSE AND COLLABORATION AGREEMENT (Filed With SEC on December 2, 2016)

THIRD AMENDMENT OF THELICENSE AND COLLABORATION AGREEMENT (Filed With SEC on December 2, 2016)

FOURTH AMENDMENT OF THE LICENSE AND COLLABORATION AGREEMENT (Filed With SEC on December 2, 2016)

THE BRIGHAM ANDWOMENS HOSPITAL, INC. EXCLUSIVE PATENT LICENSE AGREEMENT BWH Agreement No: A223064 BWH Case No: BWH 21174 (Filed With SEC on December 2, 2016)

LOAN AND SECURITY AGREEMENT (Filed With SEC on December 2, 2016)

MIRAGEN THERAPEUTICS, INC. 2008 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS:MAY 16, 2008; AMENDED JUNE 18, 2009; APRIL 9, 2012 AND OCTOBER 28, 2015 APPROVED BY THE... (Filed With SEC on December 2, 2016)

MIRAGEN THERAPEUTICS, INC. STOCK OPTION GRANT NOTICE (2008 EQUITY INCENTIVE PLAN) (Filed With SEC on December 2, 2016)

NON-EMPLOYEE DIRECTOR CASH AND EQUITYCOMPENSATION POLICY (Filed With SEC on December 2, 2016)

SUBCONTRACT AGREEMENT BETWEEN YALE UNIVERSITY AND MIRAGEN THERAPEUTICS, INC. (Filed With SEC on December 2, 2016)

INTELLECTUAL PROPERTY PURCHASE AGREEMENT (Filed With SEC on December 1, 2016)

AGREEMENT AND PLAN OF MERGER AND REORGANIZATION among SIGNAL GENETICS,INC., SIGNAL MERGER SUB, INC., and MIRAGEN THERAPEUTICS, INC. Dated as of October 31, 2016 Table of Contents (Filed With SEC on November 1, 2016)

SUPPORT AGREEMENT (Filed With SEC on November 1, 2016)

SIGNAL GENETICS, INC. AMENDMENT TO UNSECURED DEMAND PROMISSORY NOTE (Filed With SEC on November 1, 2016)

Second AMENDMENT TO THE Signal Genetics, Inc.2014 Stock Incentive Plan (Filed With SEC on August 15, 2016)

UAMSBIOVENTURES LEASEAGREEMENT (Filed With SEC on March 21, 2016)

FIRST AMENDMENT TO THE SIGNAL GENETICS, INC. 2014 STOCK INCENTIVE PLAN (Filed With SEC on June 23, 2015)

SIGNAL GENETICS, INC.By:/s/ Bennett S. LeBow Bennett S. LeBowChairman of the Board of DirectorsAcknowledged: /s/ Samuel D. Riccitelli Samuel D. Riccitelli [Signature page to... (Filed With SEC on March 27, 2015)

SIGNAL GENETICS, INC. (Filed With SEC on March 27, 2015)

UNDERWRITING AGREEMENT between SIGNAL GENETICS, INC. and AEGIS CAPITAL CORP., as Representative of the Several Underwriters (Filed With SEC on January 29, 2015)

Form of Representative’s Warrant Agreement (Filed With SEC on January 29, 2015)

OFFICE BUILDING LEASE BETWEEN OT9 OWNER, LLC, a Delaware limited liability company (LANDLORD) AND SIGNAL GENETICS, INC., a Delaware corporation (TENANT) August 18, 2014 5740-5770... (Filed With SEC on November 14, 2014)

REFERENCE LABORATORY SERVICES AGREEMENT (Filed With SEC on November 14, 2014)

REFERENCE LABORATORY SERVICES AGREEMENT FOR RESEARCH SPECIMINS (Filed With SEC on November 14, 2014)

SIGNAL GENETICS, INC. 2014 STOCK INCENTIVE PLAN (Filed With SEC on August 14, 2014)

AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on August 14, 2014)

EXCHANGE AGREEMENT (Filed With SEC on August 14, 2014)

EMPLOYMENT AGREEMENT (Filed With SEC on July 23, 2014)

AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on July 23, 2014)

Form of Representative’s Warrant Agreement (Filed With SEC on June 6, 2014)

EMPLOYMENT AGREEMENT (Filed With SEC on May 15, 2014)

AGREEMENT FOR TERMINATION OF LEASE AND VOLUNTARY SURRENDER OF PREMISES (Filed With SEC on May 15, 2014)

LICENSE AGREEMENT (Filed With SEC on April 9, 2014)

EMPLOYMENT AGREEMENT (Filed With SEC on April 9, 2014)

SIGNAL GENETICS, INC. 2014 STOCK INCENTIVE PLAN (Filed With SEC on April 9, 2014)

EXCHANGE AGREEMENT (Filed With SEC on April 9, 2014)

AMENDED AND RESTATED EMPLOYMENT AGREEMENT (Filed With SEC on April 9, 2014)

SIGNAL GENETICS, INC. RESTRICTED STOCK UNIT GRANT AGREEMENT UNDER THE 2014 STOCK INCENTIVE PLAN (Filed With SEC on April 9, 2014)

UAMS BIOVENTURES LEASE AGREEMENT (Filed With SEC on April 9, 2014)

UNDERWRITING AGREEMENT between SIGNAL GENETICS, INC. and AEGIS CAPITAL CORP., as Representative of the Several Underwriters (Filed With SEC on March 19, 2014)

ASSIGNMENT OF MEMBERSHIP INTERESTS (Filed With SEC on March 19, 2014)

LICENSE AGREEMENT (Filed With SEC on March 19, 2014)

FIRSTAMENDMENT TO LICENSE AGREEMENT (Filed With SEC on March 19, 2014)

AMENDMENT #2 to the LICENSE AGREEMENT (Filed With SEC on March 19, 2014)

AMENDMENT #3 to the LICENSE AGREEMENT (Filed With SEC on March 19, 2014)

AMENDMENT #4 to the LICENSE AGREEMENT (Filed With SEC on March 19, 2014)

REFERENCE LABORATORY SERVICES AGREEMENT (Filed With SEC on March 19, 2014)

REFERENCE LABORATORY SERVICES AGREEMENT FOR RESEARCH SPECIMENS (Filed With SEC on March 19, 2014)

AMENDED AND RESTATED SECURED DEMAND PROMISSORYNOTE (Filed With SEC on March 19, 2014)

GUARANTY AND SECURITY AGREEMENT Dated as of November 3, 2011 among SIGNAL GENETICS, LLC, MYELOMA HEALTH LLC, RESPIRA HEALTH LLC and CC HEALTH LLC, as the Borrowers, and Each Other... (Filed With SEC on March 19, 2014)

EMPLOYMENT AGREEMENT (Filed With SEC on March 19, 2014)

INCENTIVE UNITS AGREEMENT (Filed With SEC on March 19, 2014)

SIGNAL GENETICS LLC 667 MADISON AVENUE 14TH FLOOR NEW YORK, NY 10065 October 9, 2013 (Filed With SEC on March 19, 2014)

SIGNAL GENETICS, INC. INDEMNIFICATION AGREEMENT (Filed With SEC on March 19, 2014)

SIGNAL GENETICS, INC. 2014 STOCK INCENTIVE PLAN (Filed With SEC on March 19, 2014)

Category

Industry

Companies

Contracts

MIRAGEN THERAPEUTICS, INC. Contracts & Agreements